Italia markets open in 6 hours 33 minutes

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
22,74-0,73 (-3,11%)
Alla chiusura: 04:00PM EDT
22,74 0,00 (0,00%)
Dopo ore: 07:11PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente23,47
Aperto23,56
Denaro22,70 x 200
Lettera22,77 x 200
Min-Max giorno22,63 - 23,85
Intervallo di 52 settimane16,95 - 49,50
Volume944.071
Media Volume1.519.445
Capitalizzazione1,932B
Beta (5 anni mensile)1,77
Rapporto PE (ttm)N/D
EPS (ttm)-1,72
Prossima data utili08 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A50,00
  • GlobeNewswire

    Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation

    First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease ModelsCAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new preclinical data demonstrating the ability of its in vivo drug candidate, BEAM-302, to directly correct the PiZ mutation, the primary disease-causing muta

  • GlobeNewswire

    Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL

    BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therap

  • GlobeNewswire

    Beam Therapeutics to Participate in Upcoming September Investor Conferences

    CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following September investor conferences: Citi’s 18th Annual BioPharma Conference 2023 on Thursday, September 7, 2023 at 8:50 a.m. ET in Boston;2023 Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023 at 10:15 a.m. ET